Browse > Article

Acute Adverse Reactions to Gadolinium-based Intravenous Contrast Agents for MRI : Retrospective Analysis Using Computed Reporting System  

Choi, Moon-Hyung (Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Choi, Joon-Il (Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Jung, Seung-Eun (Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Ahn, Kook-Jin (Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Lee, Hae-Giu (Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Publication Information
Investigative Magnetic Resonance Imaging / v.15, no.2, 2011 , pp. 139-145 More about this Journal
Abstract
Purpose : To assess the frequency and severity of acute adverse reactions to intravenous administration of gadolinium-based contrast agents using computerized reporting system at a single large academic institution. Materials and Methods : We assessed data from electronic hospital information system from October 2008 to December 2010. Reactions were classified as mild, moderate, or severe. We compared the frequency of adverse reactions among three contrast agents (Gd-BT-DO3A, Gd-DTPA and Gd-EOB-DTPA). Results : The total number of administrated contrast agents was 33,600, and the number of administration of Gd-BT-DO3A, Gd-DTPA and Gd-EOB-DTPA were 20,824 (62%), 10,417 (31%) and 2,359 (7%), respectively. Total 39 adverse reactions were reported accounting for 0.1161% of all administrations. The incidences of adverse reactions were 0.1248% (26/39, 67%) for Gd-BT-DO3A, 0.0768% (8/39, 21%) for Gd-DTPA, and 0.2120% (5/39, 13%) for Gd-EOB-DTPA. The difference of frequencies of adverse reaction among three contrast agents was not significant. Most cases of the adverse effect were mild (35/39, 89.7%). Moderate and severe adverse reactions were encountered in two patients, respectively. Conclusion : Among Koreans, adverse effects were rare, and especially, moderate to severe adverse reactions were much rarer. There was no difference among the frequencies of adverse reactions caused by three different contrast agents.
Keywords
Magnetic resonance imaging (MRI); Contrast agents; Adverse reaction; Reporting system;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol 2010;74:e186-192   DOI   ScienceOn
2 Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005;237:89-98   DOI   ScienceOn
3 Lalli AF. Contrast media reactions: data analysis and hypothesis. Radiology 1980;134:1-12
4 Gonen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology 2001;221:763-767   DOI   ScienceOn
5 Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intraand interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006;24:1378-1385   DOI   ScienceOn
6 Murphy KP, Szopinski KT, Cohan RH, Mermillord B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656-664   DOI   ScienceOn
7 Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006;41:491-499   DOI   ScienceOn
8 Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010;194:430-434   DOI   ScienceOn
9 Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN. Assessment of adverse reaction rates during gadoteridolenhanced MR imaging in 28,078 patients. Radiology 2011;259:109-116   DOI   ScienceOn
10 Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991;13:15-20   DOI   ScienceOn
11 Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533-1538   DOI
12 Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995;196:439-443
13 Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol 1996;167:847-849
14 Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates. Br J Radiol 2006;79:368-371   DOI   ScienceOn
15 Bleicher AG, Kanal E. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191:W307-311   DOI
16 Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast- enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362   DOI   ScienceOn
17 Tne American College of Radiology. Manual on contrast media version 7 2010. www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual/FullManual.aspx
18 Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157   DOI   ScienceOn